| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
8 companies
Adage Capital Partners Gp, L.l.c. is a 10% Owner at RPRX, with reported holdings spanning 8 companies. Recent filings cover 62 purchases and 135 sales. Those positions are worth an estimated $2.1B at current prices.
Our model assigns Adage Capital Partners Gp, L.l.c. a middling insider score of 64/100, based on 40 past trades. Over a 12-month horizon, 47.5% of those trades were profitable, with an average 12-month return of +0.8%.
Adage Capital Partners Gp, L.l.c.'s largest disclosed position is in RPRX as 10% Owner, worth about $1.7B. The recent filings there lean toward selling, a net 4,301,050 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2021 | GCMG Gcm Grosvenor Inc. | 10% Owner | Sell | 386,316 | $13.68 | $5,283,873.19 | -6.4% | |
| Dec 18, 2020 | RPRX Royalty Pharma Plc | 10% Owner | Sell | 7,301,050 | $43.92 | $320,672,221.00 | -15.9% | |
| Dec 3, 2020 | 10% Owner | Sell | 1,018,465 | $12.07 | $12,287,903.70 | -56.6% | ||
| Jun 18, 2020 | RPRX Royalty Pharma Plc | 10% Owner | Buy | 3,000,000 | $28.00 | $84,000,000.00 | +7.0% | |
| Oct 11, 2017 | ADXS Ayala Pharmaceuticals, Inc. | 10% Owner | Sell | 600,000 | $4.30 | $2,580,000.00 | -12.8% | |
| Sep 28, 2017 | 10% Owner | Sell | 576,000 | $15.64 | $9,008,100.00 | -14.0% | ||
| Sep 26, 2017 | ADXS Ayala Pharmaceuticals, Inc. | 10% Owner | Sell | 1,239,323 | $4.42 | $5,474,434.74 | -20.9% | |
| Jun 12, 2017 | PBYI Puma Biotechnology, Inc. | 10% Owner | Sell | 247,260 | $80.32 | $19,858,909.96 | -6.3% | |
| Jun 5, 2017 | PBYI Puma Biotechnology, Inc. | 10% Owner | Sell | 507,128 | $87.84 | $44,544,975.45 | -11.4% | |
| May 26, 2017 | PBYI Puma Biotechnology, Inc. | 10% Owner | Sell | 1,235,700 | $75.38 | $93,144,267.69 | -21.7% |